Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway
Ming Tu, Wei Wange, Lin Cai, et al.
Tumor Biology (2016) Vol. 37, Iss. 11, pp. 14701-14709
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Stephen Bagley, Arati Desai, Gerald P. Linette, et al.
Neuro-Oncology (2018) Vol. 20, Iss. 11, pp. 1429-1438
Open Access | Times Cited: 261
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions
Stephen Bagley, Donald M. O’Rourke
Pharmacology & Therapeutics (2019) Vol. 205, pp. 107419-107419
Closed Access | Times Cited: 122
Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications
Abdul Samad Basheer, Faridah Abas, Iekhsan Othman, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4226-4226
Open Access | Times Cited: 73
Immunotherapy of glioblastoma: Recent advances and future prospects
Boyang Yuan, Guoqing Wang, Xin Tang, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 53
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements
Edoardo Agosti, Marco Zeppieri, Lucio De Maria, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15037-15037
Open Access | Times Cited: 37
Gene therapy in glioblastoma multiforme: Can it be a role changer?
Mohammad Rayati, Vahid Mansouri, Naser Ahmadbeigi
Heliyon (2024) Vol. 10, Iss. 5, pp. e27087-e27087
Open Access | Times Cited: 11
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Christopher Chang, Velina Chavarro, Jakob V. E. Gerstl, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6733-6733
Open Access | Times Cited: 9
IL13RA2 targeted alpha particle therapy against glioblastomas
Anirudh Sattiraju, Kiran Kumar Solingapuram Sai, Ang Xuan, et al.
Oncotarget (2017) Vol. 8, Iss. 26, pp. 42997-43007
Open Access | Times Cited: 75
Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options
Siddarth Kannan, Avaniyapuram Kannan Murugan, Sathyamoorthy Balasubramanian, et al.
Biochemical Pharmacology (2022) Vol. 201, pp. 115090-115090
Closed Access | Times Cited: 30
The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens
Sukrit Mahajan, Mirko H. H. Schmidt, Ulrike Schumann
Cancers (2023) Vol. 15, Iss. 7, pp. 2024-2024
Open Access | Times Cited: 17
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
Gabriele Kembuan, Joanna Y. Kim, Marcela V. Maus, et al.
Trends in cancer (2024) Vol. 10, Iss. 4, pp. 312-331
Open Access | Times Cited: 7
Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway
Tingting Zhang, Mengmeng Zhu, Jialing Ma, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 5
IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients.
Jing Zeng, Ji Zhang, Yuanzhong Yang, et al.
PubMed (2020) Vol. 12, Iss. 8, pp. 4702-4714
Closed Access | Times Cited: 36
A Systematic Review of the Metabolism of High-Grade Gliomas: Current Targeted Therapies and Future Perspectives
Lucio De Maria, Pier Paolo Panciani, Marco Zeppieri, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 724-724
Open Access | Times Cited: 4
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
Leah Gajecki, Irina V. Lebedeva, Yu-Rou Liao, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268762-jnumed.124.268762
Closed Access
miR‑29a suppresses IL‑13‑induced cell invasion by inhibiting YY1 in the AKT pathway in lung adenocarcinoma A549 cells
Yu Zhang, Shujin He, Renmei Mei, et al.
Oncology Reports (2018)
Open Access | Times Cited: 33
Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges
Jie Lu, Wen Huo, Yingze Ma, et al.
Cancer Letters (2024) Vol. 600, pp. 217185-217185
Open Access | Times Cited: 3
Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression
Mina Hashimoto, Tomomitsu Miyagaki, Reo Komaki, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00766-adv00766
Open Access | Times Cited: 14
A comparative study of the arazyme-based fusion proteins with various ligands for more effective targeting cancer therapy
Rezvan Mehrab, Hamid Sedighian, Fattah Sotoodehnejadnematalahi, et al.
Research in Pharmaceutical Sciences (2023) Vol. 18, Iss. 2, pp. 159-176
Open Access | Times Cited: 8
Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas
Kristen D. Pawlowski, Joseph Duffy, Arushi Tiwari, et al.
Cells (2023) Vol. 12, Iss. 13, pp. 1716-1716
Open Access | Times Cited: 8
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
Hany E. Marei, Asmaa Althani, Nahla Afifi, et al.
Cancer Medicine (2021) Vol. 10, Iss. 15, pp. 5019-5030
Open Access | Times Cited: 19
Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements
Xifeng Fei, Jie Wu, Haiyan Tian, et al.
Cancer Biomarkers (2024) Vol. 41, Iss. 1, pp. 1-24
Closed Access | Times Cited: 2
Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells
Yongyan Wu, Yufeng Qian, Wei Peng, et al.
PeerJ (2023) Vol. 11, pp. e15571-e15571
Open Access | Times Cited: 6
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Xiaolei Lian, Dina Kats, Samuel Rasmussen, et al.
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Cancer germline antigens and tumor-agnostic CD8+ T cell evasion
Dian Kortleve, Rui M. L. Coelho, Dora Hammerl, et al.
Trends in Immunology (2022) Vol. 43, Iss. 5, pp. 391-403
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top